Compound Testing Sample Clauses

Compound Testing. Prior to initiating discussions or negotiations with any Third Party or with Aptose with respect to the grant of a sublicense under the license granted in Section 2.1, Ohm shall conduct characterization studies of all compounds that would be included in the sublicense to determine their kinase inhibitory profile, including the inhibition of specific forms of FLT3 (FLT3-ITD, FLT3-D835Y, FLT3-ITD+D835Y, FLT3-ITD+F691L) and of BTK (BTK-wild type, BTK-C481S) using the standard assay conditions performed by Reaction Biology Corporation or equivalent procedure to characterize the molecules. Based on the results of such studies, Ohm shall identify each tested compound as either a ROFN Product or a ROFR Product, and shall provide Aptose with the results of each such test, including such identification, promptly after completion thereof.
View SourceView Similar (2)
Compound Testing. Up to 50% of the research effort expended for this contract is expected to relate directly to experiments in which we test the effects of compounds provided by the company on ciliary activity in human airway epithelial cells. The experimental protocol for a particular compound will be determined in consultation with ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇, VP of Discovery, or other appropriate company official. The test assay will use epithelial explant cultures of human nasal or bronchial epithelia attached to Transwell-Col supports. These cultures are provided by the CF Center Tissue Culture Core with all The cells are continuously superfused and ciliary activity is monitored by video microscopy. The frequency of ciliary beating is determined by FFT analysis of 10 seconds of data digitized at 1 minute intervals from a photocell positioned on the monitor over a ciliated cell. The digitization occurs in real-time, at 40 MHz; the FFT analysis occurs off-line after the experiment is over. The data are typically presented as plots of ciliary beat frequency normalized to baseline as a function of time, using the mean + SE of 4 to 6 identical experiments. --
View Source
Compound Testing. Ocera or its Sublicensee shall perform samplings and testing on a delivered lot, designed in accordance with the methods of analysis to be agreed between the parties and the Specifications, to determine whether the Compound meets the Specifications. If Ocera or its Sublicensee discovers any basis for a rejection of the Compound within 60 days after the delivery of such Compound to Ocera, Ocera shall inform Kureha promptly in writing of such rejection, and specifically state the reasons therefor. Notwithstanding the above provisions, acceptance of any delivery of Compound shall not preclude a subsequent rejection of the Compound by Ocera or its Sublicensee following discovery of latent defects in such Compound (including, without limitation, discovery of any substance that would cause the Compound to be adulterated within the meaning of the FD&C Act) within 6 months after the delivery of such Compound to Ocera, that would not reasonably be detectable in accordance with such methods of analysis, provided that Ocera or its Sublicensee notifies Kureha in writing within 5 days of discovery of such latent defect.
View Source

Related to Compound Testing

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.